financetom
Business
financetom
/
Business
/
Nature's Sunshine Products Shares Drop After Q2 Results Decline, 2024 Guidance Cut
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nature's Sunshine Products Shares Drop After Q2 Results Decline, 2024 Guidance Cut
Aug 9, 2024 1:16 PM

03:55 PM EDT, 08/09/2024 (MT Newswires) -- Nature's Sunshine Products (NATR) shares dropped past 13% in recent trading on Friday, a day after the company reported lower Q2 results and reduced its full-year net sales guidance.

The company reported Q2 adjusted earnings of $0.07 per diluted share, down from $0.12 a year earlier. A single analyst surveyed by Capital IQ expected $0.18.

Net sales for the quarter ended June 30 fell to $110.6 million from $116.5 million a year earlier. One analyst surveyed by Capital IQ expected $112.3 million.

The company reduced its 2024 net sales outlook to a range of $436 million to $445 million from an earlier guidance of $455 million to $480 million. One analyst polled by Capital IQ expects $455.8 million.

Price: 12.72, Change: -1.95, Percent Change: -13.27

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
EverQuote Q3 revenue beats expectations helped by strong showing in automotive insurance vertical 
EverQuote Q3 revenue beats expectations helped by strong showing in automotive insurance vertical 
Nov 3, 2025
Overview * EverQuote ( EVER ) Q3 revenue grows 20% yr/yr, beating analyst expectations * Adjusted EBITDA for Q3 beats analyst estimates, increasing 33% yr/yr * Company repurchased $21 mln of shares, indicating confidence in long-term growth Outlook * EverQuote forecasts Q4 2025 revenue between $174 mln and $180 mln * Company expects Q4 2025 variable marketing dollars of $46...
Sarepta's Duchenne gene therapy misses main goal in study
Sarepta's Duchenne gene therapy misses main goal in study
Nov 3, 2025
Nov 3 (Reuters) - Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal. ...
Nuvation Bio beats Q3 revenue expectations, driven by IBTROZI sales
Nuvation Bio beats Q3 revenue expectations, driven by IBTROZI sales
Nov 3, 2025
Overview * Nuvation Bio ( NUVB ) beat analysts' expectations for Q3 revenue, driven by IBTROZI sales * Company reported Q3 net loss of $55.8 mln * 204 patients started on IBTROZI in Q3, indicating strong launch progress Outlook * Company expects $25 mln milestone payment from Nippon Kayaku by year-end * Nuvation Bio ( NUVB ) plans sNDA to...
Video infrastructure provider Harmonic's Q3 revenue beats estimates, driven by SaaS growth
Video infrastructure provider Harmonic's Q3 revenue beats estimates, driven by SaaS growth
Nov 3, 2025
Overview * Harmonic Q3 2025 revenue of $142.4 mln beats analyst expectations * Adjusted EPS for Q3 2025 beats consensus, driven by SaaS growth in Video segment * Company repurchased 1.8 mln shares for $15.7 mln Outlook * Harmonic expects Q4 2025 revenue between $133 mln and $147 mln * Company anticipates Broadband revenue growth to increase in 2026 *...
Copyright 2023-2026 - www.financetom.com All Rights Reserved